Artax Biopharma has filed a notice of an exempt offering of securities to raise $8 Million in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Artax Biopharma is raising up to $8,000,000.00 in new funding. Sources indicate that as part of senior management President, Robert Armstrong played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Artax Biopharma
Artax Biopharma is a development-stage biopharmaceutical company dedicated to the development of new therapies for autoimmune and inflammatory diseases. Artax Biopharma is developing the next generation of drugs targeting the interaction between TCR and Nck, which is responsible for T-cell activation. Specific control over T-cells through TCR, provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.
To learn more about Artax Biopharma, visit http://www.artaxbiopharma.com/
Artax Biopharma Linkedin Page: https://www.linkedin.com/company/artaxbiopharma/
Contact:
Robert Armstrong, President
617-368-0676
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.